LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

Strona główna・Stock List・Editas Medicine Inc

Editas Medicine Inc

Open

SectorHealthcare

3.37 -2.03

Buy Sell

Overview

Share price change

24h

Current

Min

3.24

Max

3.52

Key metrics
By Trading Economics
Income	-19M -25M
Sales	-22M 2.8M
EPS	-0.26
Profit margin	-882.444
Employees	87
EBITDA	-19M -25M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+78.43% upside

Dividends
By Dow Jones
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	-40M 254M
Previous open	5.4
Previous close	3.37

News Sentiment

By Acuity

21%

79%

38 / 344 Ranking in Healthcare

Editas Medicine Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 maj 2026, 22:47 UTC

Earnings

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 maj 2026, 20:45 UTC

Earnings

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 maj 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 maj 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 maj 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 maj 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 maj 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 maj 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 maj 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 maj 2026, 22:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 maj 2026, 21:12 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 maj 2026, 21:00 UTC

Earnings

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 maj 2026, 20:57 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:55 UTC

Earnings

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 maj 2026, 20:48 UTC

Hot Stocks

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 maj 2026, 20:34 UTC

Earnings

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 maj 2026, 20:31 UTC

Earnings

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 maj 2026, 20:28 UTC

Earnings

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 maj 2026, 20:26 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Membership Fees $1.37B

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Net Sales $69.15B

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Comparison

Price change

Editas Medicine Inc Forecast

Price Target

By TipRanks

78.43% upside

12 Months Forecast

Average 6.37 USD 78.43%

High 15 USD

Low 4 USD

Based on 11 Wall Street analysts offering 12 month price targets forEditas Medicine Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Editas Medicine Inc - Dist in the past 3 months.

Sentiment

By Acuity

38 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.